Latest Conference Coverage

The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on navigating challenges with newly approved treatments for Alzheimer disease, and using resources efficiently. [WATCH TIME: 5 minutes]

A comparison between impaired scores on Digital Clock and Recall and impaired scores on Montreal Cognitive Assessment produced a 76% concordance.

According to diary data, caregiver's perceived reciprocity showed a substantial direct influence on the occurrence of behavioral symptoms on both the current day and the subsequent day for patients with Alzheimer disease and related dementias.

The postdoctoral fellow at the University of California San Diego discussed using CRISPR-based gene editing to alter the amyloid precursor protein gene in mice models with symptoms of Alzheimer disease. [WATCH TIME: 5 minutes]

Clinicians must be armed with fact-based information on all treatment options especially newer medications and technologies—good clinical care must be both patient-centric and knowledge-driven.

The National Multiple Sclerosis Society sponsored research fellow at Kessler Foundation talked about a research project that investigates the differences in brain structure and aging metrics among patients with multiple sclerosis from differing racial and ethnic backgrounds. [WATCH TIME: 5 minutes]

The director of the Neuroinformatics Program at the University of California, Irvine, discussed complexities with different machine learning algorithms in migraine research, including findings from the AMPP study. [WATCH TIME: 5 minutes]

The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks.

Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.

The professor of anesthesiology at Washington University in St. Louis discussed the reasons behind his presentation at the 2023 AHS Annual Meeting on engaging underserved populations in pain medicine research. [WATCH TIME: 3 minutes]

The assistant professor at Queen’s University discussed results from a pilot trial that evaluated the impact of a dyadic physical activity intervention among both caregivers and patients with multiple sclerosis. [WATCH TIME: 5 minutes]

At month 2 of a 3-month treatment period, investigators observed an improvement of 2.75 days favoring tricaprilin.

Patients with generalized myasthenia gravis treated with efgartigimod consistently exceeded treatment compared with placebo regardless of gender in age, disease duration, BMI, and thymectomy.

The duo from Indiana University School of Medicine discussed the ongoing research initiatives to better understand sleep disorders among pediatrics, and ways to improve approaches like cognitive behavioral therapy. [WATCH TIME: 4 minutes]

The postdoctoral researcher in the department of neurology at John Hopkins School of Medicine talked about indole-3-lactate as a signaling molecule in the gut-brain axis and its potential as a treatment for MS. [WATCH TIME: 5 minutes]

The undergraduate program director at the University of South Carolina discussed outdated teaching methods used in neurology, and the need to provide different hands-on approaches to students. [WATCH TIME: 5 minutes]

The director of the Buffalo Neuroimaging Analysis Center talked about the ENLIGHTEN trial, where results showed a correlation between cognitive impairment and brain volume with ozanimod. [WATCH TIME: 5 minutes]

In a cohort of patients who experienced 4-14 migraine days/month, treatment with atogepant continued to improve patients’ migraine status regardless of prior medication failures.

Findings from data on patients with various autoimmune disorders who used remibrutinib, a BTK inhibitor in development for multiple sclerosis, reported no safety concerns in laboratory analyses.

The senior vice president for Research and Training at Kessler Foundation talked about the issue of fatigue in patients with multiple sclerosis and the significant, multifaceted challenges patients face. [WATCH TIME: 5 minutes]

The duo from Indiana University School of Medicine provided perspective on the reasons for why cognitive behavioral therapy used for insomnia need to be adjusted in adolescents with the sleep disorder. [WATCH TIME: 3 minutes]

Over a 96-week period, more older patients with relapsing multiple sclerosis on diroximel fumarate achieved no evidence of disease activity-3 status vs younger patients.

In the phase 3 OPTIMUM study of ponesimod, findings showed that MRI features in patients with multiple sclerosis were significantly associated with clinical scales.

The assistant professor at Hunter College discussed the approach of systematically localizing symptoms in patients with multiple sclerosis for diagnosis based on a clinical workshop. [WATCH TIME: 5 minutes]

The assistant professor at the University of Alabama at Birmingham discussed the transition from pediatric to adult care for patients with multiple sclerosis as well as the challenges presented in diagnosis, treatment, and understanding the long-term impact of the disease. [WATCH TIME: 5 minutes]

The director of movement disorders at the Banner Sun Health Research Institute talked about how research in essential tremor is revolutionizing the diagnosis and understanding of the movement disorder. [WATCH TIME: 5 minutes]

The professor of anesthesiology at Washington University in St. Louis discussed the importance of effectively communicating and reciprocating with underserved communities that are of research interest.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the evolution of treatment for Parkinson disease and the new promising therapies patients may seen over the coming years. [WATCH TIME: 3 minutes]